Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by L. Falchero
P1.04-35 Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Related publications
P1.04-29 Second or Third Line Nivolumab Versus First Line Nivolumab in Patients With Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.04-31 Efficacy and Tolerance of Immune-Checkpoint Inhibitors in EGFR, ALK/ROS 1 Non-Small-Cell-Lung-Cancer (NSCLC): GFPC 03-2016 IMAD Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Efficacy of Nivolumab in Pre-Treated Non-Small-Cell Lung Cancer Patients Harbouring KRAS Mutations
British Journal of Cancer
Cancer Research
Oncology
Nivolumab in Metastatic Non–Small Cell Lung Cancer
Journal of the Advanced Practitioner in Oncology
Predictive Role of Plasmatic Biomarkers in Advanced Non-Small Cell Lung Cancer Treated by Nivolumab
OncoImmunology
Oncology
Allergy
Immunology
P1.04-03 Suppressive Immune Cell Profiling in Patients With Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit From Nivolumab in Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
JAMA Oncology
Cancer Research
Oncology
Long-Lasting Responses After Discontinuation of Nivolumab Treatment for Reasons Other Than Tumor Progression in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
Cancer Communications
Cancer Research
Oncology
